Monday, March 06, 2017 9:03:40 PM
In it it showed 5 previous employed directors with a combined share holding of 3,861,395 received from the 2002 & 2010 incentive options. Of those 561,981 were being offered (i.e. made eligible for sale via broker/public market)
It's reasonable say but not know that some of the heavy selling pressure that has been gradually increasing in volume since the filing is due to these individual dumping their shares, causing others to panic and when support cracked a major panic. Again these are educated guesses, but plausible. The sale of the offering shares by these employees don't have to be filed with the SEC so when they are sold is anybody's guess.
Note: that 3 of the directors are still holding onto a remaining 3,299,414 for now and the majority of the 2017 employee incentive options registered are priced at $0.54 so it should stand as good support and is positive along with recent insider buying at $0.64 imho.
Possible double bottom around $0.54ish before it goes higher on future news. Bullish with patience!
Recent BCDA News
- BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort • GlobeNewswire Inc. • 04/25/2024 01:00:00 PM
- BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results • GlobeNewswire Inc. • 03/27/2024 08:00:00 PM
- BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024 • GlobeNewswire Inc. • 03/20/2024 11:00:00 AM
- BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership • GlobeNewswire Inc. • 03/13/2024 11:00:00 AM
- BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study • GlobeNewswire Inc. • 03/12/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 01:00:21 PM
- BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure • GlobeNewswire Inc. • 03/04/2024 01:00:00 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/27/2024 09:53:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 12:00:19 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 10:06:32 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/14/2024 09:17:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2024 02:58:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 12:03:57 PM
- BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA • GlobeNewswire Inc. • 02/08/2024 12:00:00 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/06/2024 09:28:23 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/02/2024 07:06:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 12:00:22 PM
- BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference • GlobeNewswire Inc. • 01/31/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 12:00:18 PM
- BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders • GlobeNewswire Inc. • 01/03/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 12:00:27 PM
- BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction • GlobeNewswire Inc. • 12/19/2023 12:00:00 PM
- BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes • GlobeNewswire Inc. • 12/18/2023 12:16:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2023 12:00:30 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM